PTC Therapeutics (PTCT) officer sells 2,464 shares after option exercise
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Neil Gregory Almstead, Chief Technical Ops Officer of PTC Therapeutics, exercised stock options to acquire 2,464 common shares at $46.54 and on the same day sold 2,464 shares at a weighted average of $90.25 per share under a pre-arranged Rule 10b5-1 plan. Following these transactions, he holds 60,299 shares directly, 2,899 shares indirectly through his spouse, and 45,036 stock options granted January 3, 2025 that vest over four years and expire January 2, 2035.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 2,464 shares ($222,376)
Net Sell
4 txns
Insider
Almstead Neil Gregory
Role
CHIEF TECHNICAL OPS OFFICER
Sold
2,464 shs ($222K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 2,464 | $0.00 | -- |
| Exercise | Common Stock | 2,464 | $46.54 | $115K |
| Sale | Common Stock | 2,464 | $90.25 | $222K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 45,036 shares (Direct);
Common Stock — 62,763 shares (Direct);
Common Stock — 2,899 shares (Indirect, By Spouse)
Footnotes (1)
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $90.00 to $90.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.
Key Figures
Shares sold: 2,464 shares
Sale price (weighted average): $90.25 per share
Options exercised: 2,464 shares
+5 more
8 metrics
Shares sold
2,464 shares
Common stock sold in open-market transaction on 2026-07-09
Sale price (weighted average)
$90.25 per share
Weighted average price; trades ranged from $90.00 to $90.70 per share
Options exercised
2,464 shares
Common shares acquired upon stock option exercise on 2026-07-09
Exercise price
$46.54 per share
Exercise price of stock options converted into common stock
Direct holdings after transactions
60,299 shares
Common shares held directly by Neil Almstead after July 9, 2026 activity
Indirect holdings via spouse
2,899 shares
Common shares beneficially owned indirectly through spouse
Remaining stock options
45,036 shares
Stock options (right to buy) remaining after exercise; expiration 2035-01-02
10b5-1 plan adoption date
November 11, 2025
Date Neil Almstead adopted the written Rule 10b5-1 trading plan
Key Terms
Rule 10b5-1 plan, weighted average price, Stock Option (Right to Buy), vesting
4 terms
Rule 10b5-1 plan regulatory
"This transaction was effected pursuant to a written Rule 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"This price represents the weighted average price of sale transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vesting financial
"vests over four years, with 25% of the shares underlying the option vesting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transactions did PTC Therapeutics (PTCT) officer Neil Almstead report?
Neil Almstead reported exercising 2,464 stock options at $46.54 per share and selling 2,464 common shares at a weighted average of $90.25 on July 9, 2026, as part of an open-market sale sequence following the option exercise.
What stock options did Neil Almstead exercise in PTCT on July 9, 2026?
He exercised 2,464 stock options with an exercise price of $46.54 per share, converting them into an equal number of common shares. These options were granted on January 3, 2025, vest over four years, and are scheduled to expire on January 2, 2035.
What are Neil Almstead’s PTC Therapeutics (PTCT) holdings after the reported transactions?
After the reported transactions, Almstead holds 60,299 common shares of PTC Therapeutics directly, plus 2,899 shares indirectly through his spouse. He also retains 45,036 stock options (rights to buy additional shares) outstanding following the July 9, 2026 activity.
How do Neil Almstead’s option grants in PTCT vest over time?
The stock option grant reported for Almstead was made on January 3, 2025 and vests over four years. 25% vests on January 3, 2026, with an additional 6.25% of the original option amount vesting at the end of each three-month period beginning April 3, 2026.